- Jun 24, 2022
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109. Sponsor Memorial
159
- Jun 22, 2022
National Cancer Institute: Clinical Trials Information for Patients and Caregivers
National Cancer Institute: Clinical Trials Information for Patients and Caregivers National Cancer Institute: Clinical Trials Information for Patients and Caregivers Find a Clinical Trial What Are Clinical Trials? Paying for Clinical Trials Patient Safety in Clinical Trials Deciding to Take Part in a Clinical Trial Questions to Ask Your Doctor about Treatment Clinical Trials Selected NCI-Supported Trials Clinical Trials Help Build the Future of Medicine Learn more: https://ww
171
- Jun 11, 2022
Patient Education: Dexamethasaone (Decadron) and other Steroids
Patient Education: Dexamethasone and other steroids DEXAMETHASONE (DECADRON) NIH National cancer institute -cancer.gov site info on Dexamethasone This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Decadron FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/dexamethasone MedlinePlus Information on Dexamethasone A lay langua
259
- Jun 11, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM. Sponsor Hackensack Meridian Health ClinicalTrials.gov Identifier: NCT05199311 Official Title: A
103
- Jun 11, 2022
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-ASCT. Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38 subjects will be enrolled. The results from this study will inform the feasibility of pursuing a phase 3 study compar
74
- Jun 11, 2022
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor Selinexor (Xpovio) NIH National cancer institute - cancer.gov site info This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Xpovio FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/selinexor MedlinePlus Information A lay language summary of important information about
233
- Jun 11, 2022
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy w
88
- Jun 11, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage. Sponsor Fate Therapeutics ClinicalTrials.gov Identifier: NCT05182073 Official Title: A Phase I Study of FT576 as Monotherapy and in Combination With Daratumu
142
- Jun 6, 2022
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be rando
163
- Jun 5, 2022
#ASCO22 Myeloma Abstracts - 2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL
2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL #ASCO22 Myeloma Abstracts June 3-7, 2022 McCormick Place • Chicago, IL, Online #ASCO22 Abstracts #ASCO22 - June 3-7, 2022 Learn more: https://conferences.asco.org/am/attend
252
- Jun 1, 2022
#EHA2022 - Myeloma Abstracts - EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria
EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria Click here to View
#EHA2022 - MYELOMA ABSTRACTS Congress of the European Hematology Association EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria: https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/
228
- Jun 1, 2022
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment
Watch on You Tube Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MD Jan 19, 2022 Dana-Farber Cancer Institute Learn more: Dana-Farber Cancer Institute - YouTube Videos https://www.youtube.com/c/danafarber/videos Dana-Farber Cancer Institute - Multiple Myeloma Program https://www.dana-farber.org/multiple-myeloma-program/ Multiple Myeloma Patient Symposium Video Presentations https://www.dana-farber.org/health-library/videos/multiple-myeloma-patient-symposium-video-
208